VivoSeq
Other

Elderly Participants

0

Pipeline Programs↗

3

Active Trials↗

10

Companies Involved↗

Elderly Participants is an early-stage landscape with 0 programs across 10 companies. The most active players are Merck & Co., Johnson & Johnson, Eisai.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalEisai logo

Eisai

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalA

ABLi Therapeutics, Inc.

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Completed21 · 88%
Not yet recruiting1 · 4%
Active, not recruiting1 · 4%
Enrolling by invitation1 · 4%

Clinical Trials

Trial Activity

24 trials

A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
Active, not recruiting·TTonix Pharmaceuticals, Inc.·Phase 1·NCT07413367·50 enrolled
A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants
Not yet recruiting·DDong-A ST Co., Ltd.·Phase 1·NCT06391827·72 enrolled
Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants
Enrolling by invitation·OOligomerix, Inc·Phase 1·NCT05696483·88 enrolled
Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants
Completed·—·Phase 1·NCT05782179·90 enrolled
A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT02355561·12 enrolled
A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients
Completed·AABLi Therapeutics, Inc.·Phase 1·NCT04350177·101 enrolled
A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01379300·42 enrolled
A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT06625840·16 enrolled
A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants
Completed·Eisai logoEisai·Phase 1·NCT05147337·47 enrolled
Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01263314·16 enrolled
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01964651·40 enrolled
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT06411730·56 enrolled
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01887535·70 enrolled
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
Completed·Eisai logoEisai·Phase 1·NCT05745207·53 enrolled
Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)
Completed·Merck & Co. logoMerck & Co.·N/A·NCT01119703·174 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)